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Background: Molecular sensing/imaging utilizing fluorophores has been one of the most frequently used
techniques in biomedical research. As for any molecular imaging techniques, fluorescence mediated sensing always
seeks for greater specificity and sensitivity. Since fluorophores emit fluorescence while their electron energy state
changes, manipulating the local electromagnetic field around the fluorophores may be a way to enhance the
specificity and sensitivity. Gold nanoparticles (GNPs) are known to form a very strong electromagnetic field on their
surface [i.e., surface plasmon field (SPF)], upon receiving photonic energy. The level of fluorescence change by
GNP-SPF may range from complete quenching to extensive enhancement, depending upon the SPF strength,
excitation and emission wavelengths, and quantum yield of the fluorophore.
Method: Here, we report a novel design that utilizes BOTH fluorescence quenching and enhancement abilities of
the GNP in one single nano-entity, providing high specificity and sensitivity. The construct utilizes a specially
designed molecular dual-spacer that places the fluorphore at the location with an appropriate GNP-SFP strength
before and after exposed to the biomarker. A model system to test the concept was an optical signal mediator
activated by urokinase-type plasminogen activator (uPA; breast cancer secreting enzyme).
Results: The resulting contrast agent shows less than 10% of the natural fluorescence but, in the presence of uPA,
its fluorescence emission is triggered and emits its fluorescence approximately twice of the natural form.
Conclusion: This study demonstrated that our novel design of an optical contrast agent can be conditionally
activated with enhanced sensitivity, using both quenching and enhancement phenomena of fluorophores in the
electromagnetic field of the appropriate strengths (in this case, locally generated by the GNP-SPF). This entity is
similar to molecular beacon in terms of specificity but with greater sensitivity. In addition, it is not restricted to only
DNA or RNA sensing but for any designs that cause the change in the distance between the fluorophore and GNP,
upon the time of encountering biomarker of interest.
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Figure 1 A schematic diagram illustrating the fluorescence
emission level with change in the distance between a fluorophore
and a GNP. Outside the SPF field of a GNP, fluorescence level does not
get affected. As the fluorophore gets closer to the GNP, fluorescence is
enhanced until it reaches a particular distance (LL). If the distance
becomes even closer the fluorescence gets quenched, and on the GNP
surface (SS) the fluorescence becomes completely quenched.
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Molecular imaging using fluorophore as a signal mediator
is sensitive, cost-effective, rapid and user-friendly [1-4].
The emission of fluorescence is by the change in electron
energy state of the fluorophore, upon receiving photonic
energy. Therefore, placing a localized electro-magnetic
field near a fluorophore can affect the excitation state of
the fluorophore, which may be beneficially used for fluor-
escence manipulation. A practical means to create this lo-
calized field is a surface plasmon field (SPF) generated by
a metal nanoparticle [5,6]. Out of metal nanoparticles that
can generate strong SPF, gold nanoparticles (GNPs) are
most popular, particularly for biomedical research, because
of their chemical inertness and well defined surface modi-
fication method [7,8].
The level of fluorescence output affected by the SPF de-
pends on the field strength where the fluorophore is
placed [9-17]. The two main fluorophore properties that
get affected by the SPF are the fluorophore excitation
decay rate and quantum yield, and the combination of
these two ultimately determines the fluorescence level.
The GNP and fluorophore properties that affect the
fluorescence output are several, including the wavelengths
of the applied (excitation) and emission lights, intrinsic
quantum yield of the fluorophore, GNP size, and the dis-
tance between the fluorophore and GNP [18-21]. Once
the fluorophore for the application is selected, however,
the GNP size and the distance between the fluorophore
and GNP may be the only two variables to be utilized for
the purpose. Theoretical analyses on the resulting fluores-
cence level affected by the GNP-SPF with respect to the
GNP size and the distance between the fluorophore and
GNP have been performed by several research teams
[22,23]. A detailed analysis on the fluorescence outputs af-
fected by the GNP-SPF for the fluorophores frequently
used in biomedical studies has been presented in our pre-
vious publications [18,19,24].
Figure 1 is a simple, qualitative illustration of fluores-
cence intensity of a fluorophore with changes in the dis-
tance from a GNP. When the fluorophore is far from a
GNP and therefore outside the GNP-SPF, its fluorescence
output does not change. As the fluorophore moves inside
the GNP-SPF, its fluorescence becomes stronger until it
reaches a particular distance (i.e., SPF strength) from the
GNP. At this distance, the fluorescence is maximized.
After then, as it gets even closer to the GNP, its emission
level becomes reduced, and it is completely quenched on
the GNP surface. Recently, there have been many pub-
lications on utilizing the GNP-SPF for developing more
efficacious fluorescence signal mediators for biosensing
[25-28] and bioimaging [18,19,24]. They clearly demon-
strate that appropriately quenching and enhancing fluor-
escence emission by GNP-SPF can increase the selectivity
and/or sensitivity of molecular sensing, respectively.Our design, demonstrated here, is to realize a novel
fluorophore/GNP complex via taking advantage of BOTH
fluorescence quenching and enhancing ability of GNP-
SPF. The resulting complex is to emit the fluorescence
only when it encounters the biomarker of choice at an en-
hanced level, thus achieving BOTH improved selectivity
and greater sensitivity. We named this novel construct
NanoPPET (NanoParticle Plasmonic Energy Transfer).
Our first model system present here is for sensing a
biomarker with enzymatic property. Figure 2 depicts our
NanoPPET, enzyme-triggered highly sensitive fluoro-
phore/GNP complex. Briefly, the fluorophore and GNP
are connected via two spacers, one short and one long.
The distance of the short spacer (SS) is designed to be
short enough to be able to place the fluorophore within
a GNP-SPF sufficiently strong to extensively quench the
fluorescence (i.e., distance from the GNP; red arrow in
Figure 1). The SS must contain a substrate motif for the
enzyme biomarker of interest, so that it gets cleaved
when the complex encounters the biomarker. The long
spacer (LL) should be a bio-stable and biocompatible se-
quence at a length that can maximize the fluorescence
(yellow arrow in Figure 1).
The fluorescence of the complex is normally minimal
because the SS places the fluorophore in close proximity
to the GNP, resulting in fluorescence quenching. Once the
complex is placed in an environment with the biomarker,
the SS is cleaved and, the distance between the fluoro-
phore and the GNP is now determined by the length of
the LL, resulting in an enhanced fluorescence level. In this
figure, only a single pair of SS/LL is illustrated on a single
GNP, to demonstrate the concept. In actual systems, it is
suggested to place as many sets as possible, as long as the
Figure 2 Enzyme-biomarker triggered, highly sensitive fluorophore/GNP complex. The complex normally emits little fluorescence because
the SS places the fluorophore close to the GNP for fluorescence quenching. When the complex is placed in an environment with the enzyme
biomarker, SS is cleaved by the enzyme and the distance between the fluorophore and GNP becomes to the length of LL, resulting in the
fluorescence emission at an enhanced level. In this illustration, to simplify the concept, only a set of SS and LL for the GNP are shown. In reality,
multiple SS/LL-fluorophore sets are to bind to a single GNP.
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below the level of the intramolecular-fluorescence self-
quenching [29] and also the level of the particle aggrega-
tion caused by the fluorophores with hydrophobic nature.
Below are detailed descriptions on each component of
our model NanoPPET-construct.
(1) Our fluorophore was Cypate. It is a near infrared
(NIR) fluorophore with the excitation and emission
peak wavelengths at 780 and 830 nm, respectively
[30]. We selected an NIR fluorophore because NIR
penetrates deeper into tissue, which is very important
for non-invasive optical imaging. Cypate is an analog
of the FDA approved fluorophore, Indocyanine Green
(ICG) [4,31]. It is to be non-toxic to animals up to
10 μmol/kg [30], and considered to be biocompatible
although it has not yet been submitted for FDA
approval. Unlike ICG, Cypate has two COOH- side
chains, providing the ability to easily react to other
biomolecules. For our study, the COOH- side chains
were further modified to –CHO (modified Cypate;
mCy) to react to –ONH2 group of spacers (Figure 3).
(2) The biomarker selected was urokinase type
plasminogen activator (uPA), which is over-expressed
by several malignant breast cancer types [32].Figure 3 Structures of ICG, Cypate, and modified Cypate (mCy).(3) The GNP surface excluding the Cypate binding sites
was covered with self-assembled monolayer of a short,
amphiphilic molecule, HS-(CH2)11-(EG)3-OH, where
EG is ethylene glycol, and we will call this as surface coat
(SCOAT), henceforward. Its hydrophobic part –(CH2)11-
goes to the GNP surface to form tight packing and the
hydrophilic part goes to the outside, accommodating
better solubility in biofluids. For the NanoPPET, this
method of surface packing works better than covering
the surface with biopolymers of large molecular
weight [33,34], because our complex requires precisely
controlled distance between the Cypate and the GNP
for the fluorescence manipulation. SCOAT would
have minimal interference with the spacers because
the spacers are longer and more flexible than SCOAT.
(4) The short spacer is to be a peptide sequence
containing the substrate motif of uPA.
(5) The long spacer is to be a bio-polymer sequence at
a length that provides the maximum fluorescence
enhancement of Cypate for the selected GNP.
More details on (4) and (5) will follow in the upcoming
sections.
Before we designed our ultimate Cypate/spacers/GNP
NanoPPET, we needed to validate the integrity of two
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cence quenching by using a SS in the Cypate/GNP com-
plex and uPA-triggered fluorescence restoration; and (2)
identifying the LL (of a proper length) that can maximize
the Cypate fluorescence enhancement. The detailed re-
sults for the Cypate/SS/GNP complex and the Cypate/LL/
GNP complex were already reported in two of our publi-
cations (reference number 19 and 18, for the former and
the latter, respectively). Here, a brief summary of the re-
sults is provided.
Previous results
As the first step in developing our NanoPPET, it was ne-
cessary for us to determine the optimal lengths for the
short and long spacers. They were first theoretically esti-
mated for the Cypate fluorescence level (relative) with
respect to the distance from the GNP at various sizes
(Figure 4). As can be seen in the figure, for any individ-
ual GNP size, there is a distance range for fluorescence
quenching (less than 1) and another range for enhance-
ment. Our goal was, therefore, to select appropriate
GNP size and two spacer lengths for appropriate
quenching and enhancement for the selected GNP size.
A. Confirming SS integrity for conditionally signaling
optical contrast agent
A functional GNP-SS-Cypate complex should possess a
SS that (a) contains the uPA substrate motif; (b) is suffi-
ciently short for Cypate fluorescence quenching; and (c)
can be properly cleaved upon being exposed to uPA so
that the complex restores its fluorescence. The peptide
substrate motif for uPA is Gly-Gly-Arg (GGR) sequenceFigure 4 Theoretically estimated fluorescence level of Cypate
(Ex/Em, 780/830 nm) relative the fluorescence without the
influence of GNP-SPF, with change in the distance from a GNP
at sizes 5, 10, 15, and 30 nm.[35]. As shown in Figure 4, the SS would perform its
quenching role the best when it is as short as possible
and, at the same time, it should possess all three func-
tions specified above. After thorough theoretical and ex-
perimental investigations, the final SS structure was
determined to be SH-(CH2)2-Gly-Gly-Arg-Gly-Gly-Gly-
NH2. This sequence included a short hydrocarbon end-
ing with a thiol group for conjugating SS to the GNP, a
GGR sequence, and a few extra peptides for maintaining
its functional integrity as the substrate after its conjuga-
tion to GNP and to Cypate.
We then tested the SS for GNP sizes at 3.7, 8, and
16.4 nm, and 3.7 and 8 nm GNPs showed satisfactory per-
formances for quenching (Figure 5A). For the 16.4 nm
GNP the fluorescence was enhanced instead, and there-
fore this size may not be used for our purpose. We se-
lected 8.0 nm for our further studies since we later would
have to use the same size GNP for the fluorescence en-
hancement and the enhancement level is greater for larger
GNPs. Figure 5B shows the normalized fluorescence levels
before and after the 8.0 nm GNP complex was exposed to
uPA for 5 minutes. It demonstrates the feasibility of our
design for the uPA-triggered fluorescence emission.B. Confirming LL functional integrity for Cypate/GNP
complex with enhanced sensitivity
For the second component of our NanoPPET, a proper LL
for Cypate/GNP (8 nm) complex emitting maximal fluor-
escence needed to be identified. We designed the LLs with
amphiphilic molecular chains, similar to the materials
used for SCOAT, so that we could mix them at an appro-
priate ratio and conjugated them together on the GNP
surface. They were HS-(CH2)m-(EG)n-ONH2 and by chan-
ging the number m and n, the length of the spacer was
varied. For easier reaction with –ONH2 groups, mCy with
–CHO groups was used instead of Cypate with –COOH
groups (Figure 3). Our results show that the chains with
m = 12 or 16 and n = 6 offered the maximum fluorescence
enhancement, which was 200% of the fluorescence level
by mCy alone (Figure 6) and also similar to the simulation
result shown in Figure 4. We selected m = 12 for further
studies, as its structure is closer to our SCOAT and should
mix well with SCOAT, as a self-assembled monolayer.Results and discussion
The NanoPPET, shown in Figure 2, is to integrate the
functions of both complexes with short spacer and long
spacer, i.e., it normally does not fluoresce but, in the
presence of uPA, it is to emit fluorescence at an en-
hanced level. All experiments were performed at least
three times and the results were presented with the
mean and the standard deviation for their validity.
Figure 5 Confirmation of SS integrity. (A) Relative fluorescence levels of the GNP-SS-Cypate for the GNP size of 3.7, 8.0, and 16.4 nm. With 3.7
and 8 nm GNPs, the fluorescence is quenched significantly. For 16.4 nm, the fluorescence is enhanced, instead. (B) Fluorescence of 8.0 nm GNP-SS-Cypate
before and 5 minutes after adding uPA. Fluorescence is restored as uPA cleaves SS.
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Our first approach for realizing the NanoPPET was that
Cypate and the GNP (8 nm) would be connected via the
two spacers, an SS and an LL. The two spacers were,
therefore, designed to be linked using the two –COOH
groups of Cypate. Once a Cypate molecule was conju-
gated to each end of SS and LL then the other ends of
the spacers were to be bound to the GNP surface via
their thiol groups (Figure 7A).
In the process of realizing this design we encountered a
few major problems. First, in this design, Cypate needs to
be conjugated to two different spacers. It was, however,Figure 6 Relative fluorescence of GNP-LL-Cy conjugated to
8 nm GNP, for the LL spacer that provids good flourescence
enhancement for our purpose. Fluorescence is enhanced
approximately twice of the level by Cypate alone.difficult to ensure two –COOHs of a Cypate molecule
reacted with one SS and the other with LL. Secondly, as-
suming that the LL-Cypate-SS were properly formed, this
complex needed to be conjugated to the surface of a single
GNP and this task was found to be almost impossible:
Endings of both SS and LL had reactive thiol groups and
the two spacers were different in length. Therefore, the re-
action could produce a combination of several undesired
products. For examples, only one spacer would be at-
tached to a GNP and the other spacer is free; the spacers
would be attached to two different GNPs; and multiple
GNPs can be connected with multiple LL-Cypate-SS,
resulting in cross-linking. Slight cross-linking may be tol-
erable and the fluorescence may still be quenched as long
as Cypate was conjugated to GNP via the SS. Severe
cross-linking may result in product aggregation (Figure 7B)
and precipitation. In fact, due to the problems mentioned
above, we experienced serious particle aggregation and
precipitation even for the reaction with a very low reactant
concentration.
B. NanoPPET with new dual spacer design
To resolve the problems addressed above, a completely
new approach was implemented with a goal that a single
Cypate molecule should be reacted with an SS and an
LL, and that the SS/LL pair should be conjugated on a
single GNP. Our new approach was, therefore, reducing
the total reaction sites between the SS/LL pair, and
Cypate and GNP, from the original four sites to two,
while one new site is conjugated to Cypate and the
other, to a GNP. In addition, the two reaction mecha-
nisms must be different, avoiding cross-linking of result-
ing particles.
The main feature in the new design was creating a
ring-shaped dual spacer (rSP), which still possess the
properties of both SS and LL, but with only two reaction
Figure 7 An issue in designing two-spacer NanoPPET. (A) Idealistic two spacer conjugation for Cypate-dual spacer–GNP complex and (B) the
product likely formed during the Cypate and GNP reacting with two spacers: GNP cross-linking and precipitation.
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Cypate (Figure 8). To facilitate the synthesis of an appro-
priate rSP, the SS and LL sections were slightly modified.
Our original SS was HS-(CH2)2-GGRGGG-NH2. At
the –SH end, HS-(CH2)2-NH- was replaced by HS-CH2-
CH(NH2)-C(O)-, which provides a side group for con-
necting the new LL section of rSP.
The original ending –NH2 was replaced by –NH-CH
(COOH)-CH2-NH-C(O)-CH2-O-NH2, which has a side
group –COOH for connecting the other end of LL, and
the –O-NH2 ending enables an easy reaction to mCy
(modified Cypate with –CHO group). However, the
change introduced an extra length of [−CH(COOH)-
CH2-NH-C(O)-] and, to keep the length of the new SS
similar to the original one, while maintaining its func-
tion as a uPA substrate, one Glycine was removed from
the original SS, i.e., −GGRGGG- became –GRGGG-.
The original LL was HS-(CH2)12-(OCH2CH2)6-ONH2.
In the new design, Cysteine [HS-CH2-CH(COOH)-NH2]
providing an –SH group added an extra length of –CH2-
CH(COOH)-NH-. For the –ONH2 end, using H2N-CH
(COOH)-CH2-NH-C(O)-CH2-O-NH2 results in the extraFigure 8 Chemical structure of the new dual spacer. The modification
between the spacers and Cypate, and two between spacers and GNP) to t
ring-shaped dual spacer (rSP).length of C(O)-CH(NH)-CH2-NH-C(O)-CH2. The hydro-
carbon chain and PEG are connected through amide-
bond, which also introduces extra length [−NH-C(O)-].
To compensate these length increases, the –CH2- number
was reduced from 12 to 6, and EG number was reduced
from 6 to 5.
The resulting rSP became cyclo [DAP(Aoa)-PEG5-(8-
aminooctanoicacid)-Cys-Gly-Arg-Gly-Gly-Gly] (Figure 8).
The rSP has one –SH group at the one end for the GNP
surface, and –ONH2 group at the other end for reacting
with mCy. For the GNP size, 8 nm GNPs were selected, as
determined in the previous studies with the Cypate/SS/
GNP and Cypate/LL/GNP complexes. rSP and SCOAT
were mixed at 1:9 molar ratio and reacted with 8 nm
GNPs. Once the rSP-GNP complex was formed and
purified by dialysis and centrifugation, the GNP in the
resulting complex solution was quantified by the light
absorption at 520 nm. The purified rSP-GNP was then
reacted with mCy and the resultant was purified by dia-
lysis and centrifugation. The GNP and mCy in the final
product were quantified by the light absorption at
520 nm and 780 nm, respectively.was reducing the number of binding sites from four sites (two
wo (one to Cypate and one to GNP), by converting the design to a
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and GNP-rSP-mCy. The GNP-rSP-mCy spectrum shows
both GNP and mCy absorption peaks, confirming the
conjugation of mCy to GNP via rSP. The ratio between
mCy to GNP ratio for the final product GNP-rSP-mCy
was found to be approximately 110:1.
The purified GNP-rSP-mCy was then reacted with uPA
and its fluorescence was measured and compared with
that without uPA. Figure 9B shows the fluorescence level
of the GNP-rSP-mCy before and after reacting with uPA,
relative to the mCy fluorescence at the same concen-
tration without GNP. The fluorescence of GNP-rSP-mCy
before the reaction with uPA was less than 7% of mCy
alone, very close to the one for GNP-SS-Cypate shown in
Figure 5. Upon applying uPA the fluorescence of reacted
GNP-rSP-mCy started to increase, and after 5 minutes it
became up to 2.0 times of mCy alone, which is the
enhancement achieved by the 8.0 nm GNP–LL-Cypate
(Figure 6) and also very close to the simulation results
(Figure 4). The results confirmed the feasibility of NanoP-
PET concept, which utilizes both fluorescence quenching
and enhancing properties of the GNP-SPF in one single
entity to enhance both specificity and sensitivity. The
NanoPPET is similar to a molecular beacon in terms of its
specificity but not restricted only to the nucleotide sens-
ing, and it can also provide an enhanced sensitivity [36],
although further studies should be done to compare the
performances of the two.
Conclusion
We have demonstrated a method for developing a novel
optical contrast agent, NanoPPET, by appropriately utiliz-
ing GNP-SPF, for biomarker-specific fluorescence emis-
sion at an enhanced level. A model system of uPA-
triggered Cypate fluorescence emission at an enhanced
level was experimentally confirmed. Our NanoPPET
model exhibited less than 10% fluorescence before it is ex-
posed to uPA and once exposed, the fluorescence levelFigure 9 Characterization of resulting uPA-specific NanoPPET. (A) Abs
and (B) Fluorescence emission levels for free mCy, GNP-rSP-mCy complex,became 200% of the original level. Although this particular
design is for the biomarker uPA, the NanoPPET concept
can be used for any biomarker that causes a change in the
distance between a fluorophore and a GNP. The properties
of NanoPPET is similar to a molecular beacon, featuring
high specificity, but with further benefits of not being re-
stricted to the DNA or RNA sensing and, more import-
antly, providing an enhanced signal intensity. GNPs can
also provide the platform for including other molecular
entities, such as additional targeting molecules or thera-
peutic agents, as well as being able to be used as X-ray/CT
contrast agent with no further modification.
The next step for our studies will be testing the NanoP-
PET for uPA secreting celllines and animal models.
Materials and methods
A. Materials and instruments
Gold nanoparticles (GNPs; 8 nm) coated with citric acid
in aqueous solution (Ted Pella; Redding, CA) was reacted
with (1-Mercapto-11-undecyl) tri(ethylene glycol) [HS-
(CH2)11-(CH2CH2O)3; MW, 380.58] (ProChimia Surfaces;
Poland) for coating the GNP surface. Urokinase-type plas-
minogen activator (uPA) was purchased from Innovative
Research (Novi, MI). The ring-shaped spacer (rSP) was
provided by Abgent (San Diego, CA) through customized
synthesis.
Dialysis of various GNP complexes was done with Slide-
A-Lyzer Dialysis Cassettes (20 K MW Cut-Off, Thermo
Scientific; Rockford, IL). Centrifugation was done using
Eppendorf 5415 R Centrifuge (Eppendorf AG; Hamburg,
Germany). Absorption spectra of GNPs were obtained
using Beckman DU520 spectrometer (Beckman Instru-
ments, Inc.; Fullerton, CA). A sonicator (Sonic Dismem-
brator; Fisher Scientific; Chicago, IL) was used to disperse
GNPs in solutions after centrifugation.
GNP size was analyzed by a dynamic light scattering
(DLS) particle size analyzer (90Plus/BI-MAS; Brookha-
ven Instruments Co.; Holtsville, NY). Fluorescence wasorption spectra of 8.0 nm GNP, GNP-SCOAT, GNP-rSP-mCy, and mCy
and uPA treated complex.
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lecular Devices Corp.; Sunnyvale, CA) in a 96-well Uni-
plate (Whatman; Florham Park, NJ) at the excitation and
emission wavelengths of 780 and 830 nm, respectively.
B. Methods
GNP-rSP-mCy was produced by the procedure described
below:
(1) Colloidal GNP solution was concentrated ~10 times
by centrifugation at 13,000 RPM for 60 mins
followed by re-dispersion in DI water; The GNP
was quantified by the light absorption at 520 nm;
(2) rSP and SCOAT (SC) were mixed at 1:9 ratio and
diluted in ethanol at the same volume of the GNP
solution to be added;
(3) GNP solution was added to the rSC/SC mixture
solution drop-wise with stirring; the mixture was
stirred for 4 hrs at room temperature. According to
Duchesne et al. [33], a tightly packed, mixed monolayer
of SC and peptide on GNP surface corresponds to 3.6
molecule/nm2-GNP surface area. Here, for the amount
of rSP and SC, 60 molecule/nm2-GNP surface-area
(excess by ~15 times) was used in the reaction;
(4) After the reaction, the solution was placed in a
dialysis cassette (20 K MW cut-off ) and the cassette
was placed in 2 L of DI water in dark with stirring,
overnight.
(5) The dialyzed sample was then centrifuged at 13000
RPM for 60 min. The pellet was re-dispersed in
1 mL of DI water and sonicated for 5 minutes.
(6) mCy was dissolved in ethanol at 2.5 mM; a blocking
agent, IN-(CH2)2-ONH2 (BLK) was added to mCy
solution at a 1:1 molar ratio and reacted in dark, at
room temperature, overnight. Addition of BLK is to
block one of the two reactive –CHO groups of mCy,
and it also increases the hydrophicility of mCy.
(7) mCy-BLK was added to the solution from step (5)
at 0.3 molecule/nm2-GNP surface and reacted with
stirring, for 4 hrs, in dark, at room temperature.
(8) The solution from step (7) was dialyzed in 2 L of DI
water with stirring, in dark, overnight, to remove
unreacted mCy;
(9) The dialyzed sample was then centrifuged at 13000
RPM for 60 min. The pellet was re-dispersed in
1 mL of DI water and sonicated for 5 minutes.
(10) The GNP and mCy in the solution were quantified
by UV-Visible spectroscopy.
(11)The NanoPPET solution resulted from step (10) was
diluted to 50–100 nM mCy concentration, and placed
in a 96-well plate. Multiple wells were filled with
duplicates of NanoPPET solution and control samples
with mCy-BLK at the same mCy concentration, at
200 μL for each well. Small volume (5 μL) of uPA so-
lution was added to the wells to result in aconcentration of 1030 units/ml (i.e., a sufficient
amount). The fluorescence of the samples was
measured before and after adding uPA, until little
change in fluorescence was observed. Fluorescence
of samples without uPA addition, but with the same
volume (5 μL) of water addition was also measured
as a negative control.
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